China: CARSgen Therapeutics prices HK IPO at top of range to raise HK$3.1bn

By
Nick Herbert
-
CAR T-cell therapy. Artificial leukocyte receptors are proteins that have been engineered for cancer immunotherapy (killing of tumor cells). genetically engineered. Vector diagram for medical, educational and science use

CARSgen Therapeutics, a biopharmaceutical company with operations in China and the US, has launched a global offering of 94.7m primary shares at a the top of the indicative price range at HK$29.60 – HK$32.80, according to IFR, to raise maximum proceeds of HK$3.1bn. CARSgen is focused on CAR-T cell therapies for the treatment of haematological…

You must be a HMI Subscriber to view this content.

Subscribe Now »

RELATED ARTICLESMORE FROM AUTHOR